CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

NCT07008872 | Not Yet Recruiting

• 1 other identifier: XB-20240912-1
• Study Type: interventional
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

CD7 molecules are thought to be associated with disease aggressiveness, drug resistance, and poor prognosis. Intensive chemotherapy, immunotherapy, hematopoietic stem cell transplantation (HSCT) and other treatment regimens have achieved remarkable results in the treatment of hematologic malignant diseases. Nevertheless, patients with hematologic malignancies may still tolerate acquired therapy during the above treatments, and molecular targeted immunotherapy provides a safe, efficient and specific treatment for such patients The scheme has attracted more and more researchers' attention. The use of CD7 molecules as a new target for molecularly targeted anti-tumor therapy may provide a new research direction for the treatment of CD7 relapsed/refractory hematologic malignancies.

Conditions

CD7+ Lymphoma; CD7+ Acute Leukemia

Keywords

CD7 CART, AL, lymphoma

Outcome Measures

Primary Outcomes (3)

• Evaluate the safety of CD7 CAR-T cell therapy in relapsed/refractory malignant lymphoma/acute leukemia

  the incidence and severity of immune therapy related toxic reactions (irAEs)

  up to one month after the CAR-T infusion

• Evaluate the effcacy of CD7 CAR-T cell therapy in relapsed/refractory malignant lymphoma/acute leukemia

  CR rate on M1 and M3

  one month and three month after the CAR-T infusion

• Evaluate the effcacy of CD7 CAR-T cell therapy in relapsed/refractory malignant lymphoma/acute leukemia

  ORR(CR and PR) on M1 and M3

  one month and three month after the CAR-T infusion

Secondary Outcomes (7)

• long-term efficacy

  up to one year after the CAR-T infusion

• long-term efficacy

  up to one year after the CAR-T infusion

• long-term efficacy

  up to one year after the CAR-T infusion

• Cell pharmacokinetics Dynamic indicators

  Day7, Day10, Day14, Day28 after the CAR-T infusion

• Cell pharmacokinetics Dynamic indicators

  Day7, Day10, Day14, Day28 after the CAR-T infusion

Study Arms (1)

CD7 CAR-T

EXPERIMENTAL

For intravenous infusion

Biological: CD7 CART

Interventions

CD7 CART BIOLOGICAL

For intravenous infusion

CD7 CAR-T

Eligibility Criteria

• Age: 14 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must meet all of the following criteria to be enrolled:
• Subjects diagnosed with relapsed/refractory lymphoma/leukemia:
• Relapsed/refractory T-cell malignant lymphoma: patients who have not remission and recurrence after at least 2 courses of standardized second-line or above treatment (including hematopoietic stem cell transplantation).
• Relapsed/refractory T-cell acute lymphocytic or myeloid leukemia meeting any of the following criteria:
• i) Relapse: After achieving complete remission with a standard treatment regimen (including hematopoietic stem cell transplantation), blasts appear in peripheral blood or bone marrow (proportion\>5%), or extramedullary diseases occur; ii) Refractory: No complete remission after at least two courses of standard induction therapy.
• Bone marrow flow cytometry detected tumor cells as CD7 and/or extramedullary lesions with a clear diagnosis of CD7 by pathological immunohistochemistry at the time of enrollment screening;
• If tumor cells are detected in peripheral blood during enrollment screening, flow cytometry must be used to detect that the immunophenotype of tumor cells on the surface of tumor cells is both negative for CD4 and CD8. If the immunophenotype on the surface of peripheral blood tumor cells is not CD4 and CD8 negative, the proportion of peripheral blood tumor cells must be ≤1%;
• Expected survival greater than 3 months from the date of signing the informed consent form;
• Subjects with a performance status of 0\~2 in the Eastern Cooperative Oncology Group (ECOG) score;
• years old≤ age ≤ 75 years old, male or female;
• HGB at least ≥70g/L, blood transfusion is available;
• Liver and kidney function, heart and lung function meet the following requirements:
• creatinine ≤1.5×ULN;
• left ventricular ejection fraction ≥50%;
• Oxygen saturation \>90%;

You may not qualify if:

• One of the following cardiac criteria occurs: atrial fibrillation; Myocardial infarction within the past 12 months; Prolonged QT syndrome or secondary QT Extension, to be determined by the researcher. Echocardiography with LVSF\<30% or LVEF\<50%; Clinically significant pericardial effusion; Heart function Incomplete NYHA III or IV (confirmed by echocardiography within 12 months after treatment);
• Active GVHD;
• Have a history of severe pulmonary dysfunction;
• Merge other advanced malignant tumors;
• Combination of severe or persistent infections that cannot be effectively controlled;
• Combination of severe autoimmune diseases or congenital immunodeficiency;
• Active hepatitis (hepatitis B virus deoxyribonucleic acid \[HBV-DNA ≥ 500 IU/ml and abnormal liver function\] or anti hepatitis C virus Positive for HCV Ab, HCV-RNA above the detection limit of the analytical method, and abnormal liver function;
• Human immunodeficiency virus (HIV) infection or syphilis infection;
• Have a history of severe allergies to biological products (including antibiotics);
• There are central nervous system disorders, such as uncontrolled epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, etc;
• Female patients who are pregnant or breastfeeding, or have a pregnancy plan within 12 months;
• The researcher believes that there may be situations that increase the risk to the subjects or interfere with the test results.

Sponsors & Collaborators

• Qi deng: lead
• Hebei Taihe Chunyu Biotechnology Co., Ltd: collaborator

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: May 19, 2025
• First Posted: June 6, 2025
• Study Start: June 1, 2025
• Primary Completion (Estimated): May 31, 2027
• Study Completion (Estimated): May 31, 2027
• Last Updated: June 6, 2025

Record last verified: 2025-05